Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists
Abstract Background and aims Type 2 diabetes mellitus (T2DM) is usually complicated by cardiovascular diseases, hyperglycemia, and obesity, which worsen the outcome for the patient. Since recent evidence underlines the epigenetic role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the ma...
Saved in:
Main Authors: | Xiaolei Miao, Maryam Davoudi, Zahra Alitotonchi, Ensieh Sadat Ahmadi, Fatemeh Amraee, Ashraf Alemi, Reza Afrisham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13098-025-01581-3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01) -
Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01) -
Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01) -
Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01) -
Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)